Tags

Type your tag names separated by a space and hit enter

Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects.
Atherosclerosis 1988; 73(1):13-22A

Abstract

We studied the effects of dietary supplementation with an encapsulated fish oil concentrate (Maxepa) on platelet function, fibrinolysis, and plasma lipids and lipoproteins in 9 normal subjects, 10 patients with type IV hyperlipoproteinemia, and 6 with type IIB hyperlipoproteinemia. After a baseline period, the subjects crossed over randomly between treatment periods with Maxepa (providing 3.24 g eicosapentaenoic acid and 2.16 g docosahexaenoic acid per day) and safflower oil (used as a control), given for 6 weeks each. Administration of Maxepa led to a slight prolongation of the bleeding time in all groups and to modest inhibition of platelet aggregation in the type IV hyperlipoproteinemics and normal subjects, with partial (41%) inhibition of thromboxane synthesis from baseline levels noted in the normal group. Plasma total fibrinolytic actively did not change significantly in any group. Maxepa treatment resulted in a marked decrease in triglyceride and VLDL-cholesterol and a slight increase in HDL-cholesterol was noted after Maxepa in the type IV hyperlipoproteinemics (4.11 +/- 0.13 mmol/l vs. 3.10 +/- 0.16 mmol/l, Maxepa vs. safflower oil). We conclude that dietary supplementation with fish oil results in a relatively minor degree of inhibition of platelet function in normal and hyperlipoproteinemic subjects, and a potentially adverse increase in LDL-cholesterol in type IV hyperlipoproteinemics.

Authors+Show Affiliations

Department of Pathology, University of Kansas School of Medicine, Kansas City.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3178928

Citation

Zucker, M L., et al. "Effects of Dietary Fish Oil On Platelet Function and Plasma Lipids in Hyperlipoproteinemic and Normal Subjects." Atherosclerosis, vol. 73, no. 1, 1988, pp. 13-22.
Zucker ML, Bilyeu DS, Helmkamp GM, et al. Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis. 1988;73(1):13-22.
Zucker, M. L., Bilyeu, D. S., Helmkamp, G. M., Harris, W. S., & Dujovne, C. A. (1988). Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis, 73(1), pp. 13-22.
Zucker ML, et al. Effects of Dietary Fish Oil On Platelet Function and Plasma Lipids in Hyperlipoproteinemic and Normal Subjects. Atherosclerosis. 1988;73(1):13-22. PubMed PMID: 3178928.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. AU - Zucker,M L, AU - Bilyeu,D S, AU - Helmkamp,G M, AU - Harris,W S, AU - Dujovne,C A, PY - 1988/9/1/pubmed PY - 1988/9/1/medline PY - 1988/9/1/entrez SP - 13 EP - 22 JF - Atherosclerosis JO - Atherosclerosis VL - 73 IS - 1 N2 - We studied the effects of dietary supplementation with an encapsulated fish oil concentrate (Maxepa) on platelet function, fibrinolysis, and plasma lipids and lipoproteins in 9 normal subjects, 10 patients with type IV hyperlipoproteinemia, and 6 with type IIB hyperlipoproteinemia. After a baseline period, the subjects crossed over randomly between treatment periods with Maxepa (providing 3.24 g eicosapentaenoic acid and 2.16 g docosahexaenoic acid per day) and safflower oil (used as a control), given for 6 weeks each. Administration of Maxepa led to a slight prolongation of the bleeding time in all groups and to modest inhibition of platelet aggregation in the type IV hyperlipoproteinemics and normal subjects, with partial (41%) inhibition of thromboxane synthesis from baseline levels noted in the normal group. Plasma total fibrinolytic actively did not change significantly in any group. Maxepa treatment resulted in a marked decrease in triglyceride and VLDL-cholesterol and a slight increase in HDL-cholesterol was noted after Maxepa in the type IV hyperlipoproteinemics (4.11 +/- 0.13 mmol/l vs. 3.10 +/- 0.16 mmol/l, Maxepa vs. safflower oil). We conclude that dietary supplementation with fish oil results in a relatively minor degree of inhibition of platelet function in normal and hyperlipoproteinemic subjects, and a potentially adverse increase in LDL-cholesterol in type IV hyperlipoproteinemics. SN - 0021-9150 UR - https://www.unboundmedicine.com/medline/citation/3178928/Effects_of_dietary_fish_oil_on_platelet_function_and_plasma_lipids_in_hyperlipoproteinemic_and_normal_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0021-9150(88)90158-X DB - PRIME DP - Unbound Medicine ER -